Maia Biotechnology, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
AMEX
MAIA Biotechnology reports significant clinical progress for its lead cancer drug ateganosine, initiates Phase 3 trials, and strengthens its financial position with recent capital raises, despite ongoing net losses.
AMEX
MAIA Biotechnology's 10-K filing highlights positive survival data from its THIO-101 Phase 2 clinical trial in non-small cell lung cancer (NSCLC) and outlines the company's financial status and future plans.
AMEX
MAIA Biotechnology's 10-K filing details its securities, clinical trial progress, and intellectual property, highlighting its focus on telomere-targeting cancer therapies.